Sanofi

The Paris-based pharmaceutical giant that co-developed Dupixent with Regeneron and handles its international commercialization. - Co-developer and international marketer of Dupixent; projects sales reaching approximately $24 billion by 2030

When the Food and Drug Administration (FDA) approved Dupixent for severe eczema in 2017, it was one drug for one disease. Nine years later, the same molecule has been approved for nine separate conditions, from asthma to a chronic fungal sinus infection that previously had no approved treatment at all. The latest approval, granted on February 24, 2026, covers allergic fungal rhinosinusitis (AFRS), a condition that traps patients in a cycle of repeated sinus surgeries. In a pivotal trial, Dupixent reduced the need for additional surgeries and steroid courses by 92%.

Updated 4 days ago

Global pharmaceutical company headquartered in Paris, with a growing immunology portfolio anchored by the $3.68 billion Principia Biopharma acquisition. - Developing rilzabrutinib across multiple autoimmune indications

For 50,000 Americans living with warm autoimmune hemolytic anemia, there has never been a treatment specifically designed for their disease. On February 9, 2026, the Food and Drug Administration (FDA) granted breakthrough therapy designation to rilzabrutinib—marking the first time a Bruton's tyrosine kinase (BTK) inhibitor has reached this milestone for the condition. The designation signals the FDA's recognition that this drug may offer substantial improvement over existing therapies.

Updated Feb 9

French pharma giant racing to build a €10 billion vaccine business by 2030 through aggressive M&A. - Acquiring Dynavax to strengthen adult vaccine portfolio

Sanofi dropped $2.2 billion on December 24, 2025 to acquire Dynavax, a California biotech with a two-dose hepatitis B vaccine and a shingles shot in development. The 39% premium signals desperation: Sanofi is playing catch-up in a vaccine market projected to hit $37.2 billion by 2033, driven by the largest aging population in human history. By 2050, 2.1 billion people will be over 60—triple the population over 80. The deal is expected to close in Q1 2026 pending Hart-Scott-Rodino antitrust clearance and other customary regulatory approvals.[1]

Updated Feb 4

French pharmaceutical giant with €43 billion in annual revenue and a struggling MS franchise. - Seeking FDA guidance after tolebrutinib rejection

The FDA just rejected Sanofi's tolebrutinib for progressive multiple sclerosis on December 28, 2025—a crushing blow for a drug that had won Breakthrough Therapy status and became the first BTK inhibitor approved anywhere in the world. Meanwhile, Roche's rival drug fenebrutinib is racing toward approval after stunning Phase 3 victories, and Merck's evobrutinib crashed out entirely. Three pharma giants bet billions that brain-penetrating BTK inhibitors could finally slow the relentless neurodegeneration that leaves MS patients in wheelchairs. Only one looks likely to reach the finish line first.

Updated Dec 28, 2025